BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32077005)

  • 1. Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma.
    Ueberroth BE; Khan A; Zhang KJ; Philip PA
    J Gastrointest Cancer; 2021 Mar; 52(1):160-168. PubMed ID: 32077005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
    Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
    BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer.
    Sierzega M; Lenart M; Rutkowska M; Surman M; Mytar B; Matyja A; Siedlar M; Kulig J
    Ann Surg Oncol; 2017 Mar; 24(3):808-815. PubMed ID: 27770341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
    Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
    JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).
    Xiang ZJ; Hu T; Wang Y; Wang H; Xu L; Cui N
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
    JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.
    Zhou H; Zhang Y; Wei X; Yang K; Tan W; Qiu Z; Li S; Chen Q; Song Y; Gao S
    Cancer Med; 2017 Nov; 6(11):2745-2756. PubMed ID: 28980417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
    Chen Y; Yan H; Wang Y; Shi Y; Dai G
    Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma.
    Murphy MM; Simons JP; Ng SC; McDade TP; Smith JK; Shah SA; Zhou Z; Earle CC; Tseng JF
    Ann Surg Oncol; 2009 Nov; 16(11):2968-77. PubMed ID: 19669839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
    Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
    Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Resected Patients with Pancreatic Adenocarcinoma.
    Fang LP; Xu XY; Ji Y; Huang PW
    World J Surg; 2018 Nov; 42(11):3736-3745. PubMed ID: 30014292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio.
    Bhatti I; Peacock O; Lloyd G; Larvin M; Hall RI
    Am J Surg; 2010 Aug; 200(2):197-203. PubMed ID: 20122680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
    Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
    World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis.
    Singal V; Singal AK; Kuo YF
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):715-22. PubMed ID: 22246279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.
    Qi Q; Geng Y; Sun M; Wang P; Chen Z
    Pancreatology; 2015; 15(2):145-50. PubMed ID: 25641673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy.
    Teo M; Mohd Sharial MS; McDonnell F; Conlon KC; Ridgway PF; McDermott RS
    Tumori; 2013; 99(4):516-22. PubMed ID: 24326841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
    Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
    Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.